This activity is supported by an educational grant from AbbVie, Celgene, Genentech, and Gilead.

Defining the New Treatment Paradigm for Patients with Chronic Lymphocytic Leukemia

Jeffrey Jones, MD/MPH
Ohio State University Comprehensive Cancer Center

Mollie Moran, CNP
The James Cancer Hospital at The Ohio State University

Oncology care is undergoing dynamic changes across tumor types with novel therapies being developed at a rapid pace. Within the past 3 years, the FDA has approved five new treatment options for patients with CLL. While these advances improve patient outcomes and the quality of care, the need for advanced practitioners (APs) to stay up to date and informed in order to translate these advances into the clinical setting is daunting. This educational activity will provide APs with important information on the diagnostic workup, risk assessment/prognostic indicators, optimizing treatment selection, response monitoring, mechanism of actions, and side effect management of newer therapies.


Download Podcast


Download Transcript


Download Slides


Download Slides & Transcripts


These CME/CE/CPE accredited activities are jointly provided by

JADPRO CE Logo Harborside Press Logo APSHO Logo Annenberg Logo
Copyright © 2010-2020 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.